BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
Podcasting since 2025 • 20 episodes
BioBiz Buzz
Latest Episodes
20. Redefining HIV Treatment and Prevention: Gilead’s Next Chapter
In this episode of BioBiz Buzz, your host Mike Ward sits down with Dr. Jared Baeten, Senior Vice President for Clinical Development and Head of the Virology Therapeutic Area at Gilead Sciences, to explore how new data from CROI 2026 could signa...
•
Season 2
•
Episode 1
•
34:00
19. From Genesis to Revelations: Winners & Losers in Pharma’s Most Volatile Year
2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with Mike Ward, Global Head ...
•
Season 1
•
Episode 19
•
25:09
18. Putting solid tumours under the T-knife: how a next-gen TCR aims to crack them
Engineered T-cell receptor (TCR) therapies promise to do for solid tumours what chimeric antigen receptor T-cell (CAR-T) therapies have done for haematological malignancies.The two approaches are conceptually similar – each involves the ...
•
Season 1
•
Episode 18
•
22:44
17. Democratizing Drug Discovery: How Lilly ExploR&D Is Changing the Biotech Playbook
The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D capabilities or negotiate partnerships on terms controlled by B...
•
Season 1
•
Episode 17
•
27:46
16. The Smart Money Talks: Inside Sofinnova's Bold €650M Fundraise
In a fundraising environment marked by cautious institutional investors, tightening belts, and widespread scepticism about early-stage venture capital, Sofinnova Partners has just closed its flagship Capital XI fund at €650 million, significant...
•
Season 1
•
Episode 16
•
25:02
